Skip to main content

Table 3 Left ventricular dysfunction and structural cardiac abnormality progression

From: Investigation of association of genetic variant rs3918242 of matrix metalloproteinase-9 with hypertension, myocardial infarction and progression of ventricular dysfunction in Irish Caucasian patients with diabetes: a report from the STOP-HF follow-up programme

LVD progression

All (n = 498)

CC (n = 358)

CT/TT (n = 140)

OR

P

LVDD progression, n (%)

111 (22.3)

82 (22.9)

29 (20.7)

1.24 [0.77, 1.99]

ns

LVSD progression, n (%)

19 (3.8)

9 (2.5)

10 (7.1)

2.98 [1.19, 7.51]

0.015

Any LVD progression, n (%)

127 (25.5)

89 (24.9)

38 (27.1)

1.13 [0.72, 1.75]

ns

LAVI progression

41 (8.2)

24 (6.7)

17 (12.1)

1.92 [1.0, 3.70]

0.047

LVH progression, n (%)

33 (6.6)

24 (6.7)

9 (6.4)

0.96 [0.43, 2.11]

ns

Any LVD or SCA progression, n (%)

166 (33.3)

114 (31.8)

52 (37.1)

1.40 [0.91, 2.14]

ns

  1. LVD left ventricular dysfunction, LVDD left ventricular diastolic dysfunction, LVSD left ventricular systolic dysfunction, LVH left ventricular hypertrophy, LAVI left atrial volume index, SCA structural cardiac abnormality
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us